Reply to Varghese et al.'s response to Wu et al. — “Cost effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong”

References

• Varghese L, Mungall B, Zhang X-H, Hoet B. Response to Wu et al.—Cost-effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong. Hum Vaccin Immunother 2016 [Epub ahead of print]; PMID:27459265; http://dx.doi.org/10.1080/21645515.2016.1192738
   Google Scholar
• Davis SM, Deloria-Knoll M, Kassa HT, O'Brien KL. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine 2013; 32:133-45; PMID:23684824; http://dx.doi.org/10.1016/j.vaccine.2013.05.005
   PubMed Web of Science ®Google Scholar
• Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J 2012; 31:297-301; PMID:22330166; http://dx.doi.org/10.1097/INF.0b013e318247ef84
   PubMed Web of Science ®Google Scholar
• Wu DB, Chaiyakunapruk N, Chong HY, Beutels P. Choosing between 7-, 10-and 13-valent pneumococcal conjugate vaccines in childhood: A review of economic evaluations (2006–2014). Vaccine 2015; 33(14):1633-58; PMID:25681663; http://dx.doi.org/10.1016/j.vaccine.2015.01.081
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15(3):301-9; PMID:25656600; http://dx.doi.org/10.1016/S1473-3099(14)71081-3
   PubMed Web of Science ®Google Scholar
• Waight PA, Andrews NJ, Ladhani NJ, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015; 15(5):535-43; PMID:26008826; http://dx.doi.org/10.1016/S1473-3099(15)70044-7
   PubMed Web of Science ®Google Scholar
• Griffin MR, Mitchel E, Moore MR, Whitney CG, Grijalva CG, Centers for Disease Control and Prevention (CDC). Declines in pneumonia hospitalizations of children aged< 2 years associated with the use of pneumococcal conjugate vaccines—Tennessee, 1998–2012. MMWR Morb Mortal Wkly Rep 2014; 63(44):995-8; PMID:25375070
   PubMed Web of Science ®Google Scholar
• Jokinen J, Rinta-Kokko H, Siira L, Palmu AA, Virtanen MJ, Nohynek H, Virolainen-Julkunen A, Toropainen M, Nuorti JP. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children–a population-based study. PLoS One 2015; 10:e0120290; PMID:25781031; http://dx.doi.org/10.1371/journal.pone.0120290
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Welfare. http://www.thl.fi/en/web/thlfi-en/topics/information-packages/incidence-of-invasive-pneumococcal-disease-in-finland. Accessed 10th June 2016.
   Google Scholar
• Andrade AL, Minamisava R, Policena G, Cristo EB, Domingues CM, de Cunto Brandileone MC, Almeida SC, Toscano CM, Bierrenbach AL. Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: A time-series analysis. Hum Vaccines Immunother 2016; 12(2):285-92; PMID:26905679; http://dx.doi.org/10.1080/21645515.2015.1117713
   PubMed Web of Science ®Google Scholar
• Suaya JA, 大野孝順  , Betsy H. 臨床研究・症例報告 日本における定期接種ワクチンとしての小児用 13 価肺炎球菌結合型ワクチンの 10 価肺炎球菌結合型ワクチンに対する費用対効果分析. 小児科臨床 2015; 68(6):1197-217.
   Google Scholar
• Hackel M, Lascols C, Bouchillon S, Hilton B, Morgenstern D, Purdy J. Serotype prevalence and antibiotic resistance in Streptococcus pneumoniae clinical isolates among global populations. Vaccine 2013; 31(42):4881-7; PMID:23928466; http://dx.doi.org/10.1016/j.vaccine.2013.07.054
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201(1):32-41; PMID:19947881; http://dx.doi.org/10.1086/648593
   PubMed Web of Science ®Google Scholar
• Choi EH, Kim SH, Eun BW, Kim SJ, Kim NH, Lee J, Lee HJ. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 2008; 14(2):275; PMID:18258121; http://dx.doi.org/10.3201/eid1402.070807
   PubMed Web of Science ®Google Scholar
• Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N.. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis 2009; 199(6):776-85; PMID:19434927; http://dx.doi.org/10.1086/597044
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr 2010; 10:4; PMID:20122261; http://dx.doi.org/10.1186/1471-2431-10-4
   PubMed Web of Science ®Google Scholar
• Domingues CM, Verani JR, Montenegro Renoiner EI, de Cunto Brandileone MC, Flannery B, de Oliveira LH, Santos JB, de Moraes JC, Brazilian Pneumococcal Conjugate Vaccine Effectiveness Study Group. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med 2014; 2:464-71; PMID:24726406; http://dx.doi.org/10.1016/S2213-2600(14)70060-8
   PubMed Web of Science ®Google Scholar
• Institute of Environmental Science and Research (ESR). Invasive pneumococcal disease in New Zealand. 2013 Surveillance report. Porirua: ESR. 2014; https://surv.esr.cri.nz/surveillance/IPD.php?we_objectID=4061. Accessed 8th June 2016.
   Google Scholar
• Institute of Environmental Science and Research Ltd. Invasive Pneumococcal Disease Quarterly Report. October−December 2014. https://surv.esr.cri.nz/PDF_surveillance/IPD/2014/2014Q4_IPDReport.pdf. Accessed 8th June 2016.
   Google Scholar
• GSK Clinical Study Report 112595. ( 10PN-DIT-053) accessed 15 Apr 2015 from http://www.gsk-clinicalstudyregister.com/study/112595#csr
   Google Scholar
• Joint Committee on Vaccination and Immunisation. Minutes of the JCVI pneumococcal subcommittee meeting, 3 February 2016. https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation#minutes. Accessed 8th June 2016.
   Google Scholar
• Greenberg D, Givon-Lavi N, Ben-Shimol S, Ziv JB, Dagan R. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children < 5 years. Vaccine 2015; 33(36):4623-9; PMID:26116251; http://dx.doi.org/10.1016/j.vaccine.2015.06.062
   PubMed Web of Science ®Google Scholar
• Carmona-Martinez A. Immunogenicity and safety of 11- and 12- valent  pneumococcal non-typeable haemophilus influenzae Protein- D-Conjugate Vaccines in Infants: Phase II Study. Poster 196 ISPPD 2014.
   Google Scholar
• Tregnaghi MW, Sáez-Llorens X, López P, Abate H, Smith E, Pósleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial. PLoS Med 2014; 11(6):e1001657; PMID:24892763; http://dx.doi.org/10.1371/journal.pmed.1001657
   PubMed Web of Science ®Google Scholar
• Dagan R, Pelton S, Bakaletz L, Cohen R. Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease. Lancet Infect Dis 2016; 16(4):480-92; PMID:27036355; http://dx.doi.org/10.1016/S1473-3099(15)00549-6
   PubMed Web of Science ®Google Scholar
• Stamboulidis K, Chatzaki D, Poulakou G, Ioannidou S, Lebessi E, Katsarolis I, Sypsa V, Tsakanikos M, Kafetzis D, Tsolia MN. The impact of the heptavalent pneumococcal conjugate vaccine on the epidemiology of acute otitis media complicated by otorrhea. Pediatr Infect Dis J 2011; 30(7):551-5; PMID:21297521; http://dx.doi.org/10.1097/INF.0b013e31821038d9
   PubMed Web of Science ®Google Scholar
• Dagan R, Ben-Shimol S, Leibovitz E, Givon-Lavi N. Implementation of PCV7/PCV13 in Israel had a signifi cant impact on both pneumococcal and non-pneumococcal complex otitis media rates. IDWeek; Philadelphia, PA, USA; Oct 8–12, 2014.
   Google Scholar
• Linden MVD, Falkenhorst G, Perniciaro S,Imöhl M. Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany. PLoS One 2015; 10(7): e0131494.
   Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH, Zansky SM, Rosen JB, Reingold A, Scherzinger K, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med 2016; 4(5):399-406; PMID:26987984
   PubMed Web of Science ®Google Scholar
• Van der Linden et al. Effectiveness Of pneumococcal conjugate vaccines (Pcv7, Pcv10 And Pcv13) against invasive pneumococcal disease among children under two years of age in Germany. Brighton, UK: European Society for Paediatric Infectious Diseases; May 10-14, 2016. Accessed 14 Apr 2016.
   Google Scholar